Dianabol vs VIP
Well Studied vs Extensively Studied
avoid Mechanism-based · 60% Both Dianabol and VIP carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Dianabol VIP
Weight 300.44 Da 3,326 Da
Half-life ~4-6 hours 1-2 minutes
Chain — 28 amino acids
Type 17-alpha-alkylated anabolic steroid (C20H28O2) Neuropeptide
Key Benefits
Dianabol
01 Rapid and dramatic increases in muscle mass and bodyweight
02 Significant strength gains within the first 1-2 weeks
03 Enhanced nitrogen retention and protein synthesis
04 Improved glycogenolysis and muscular endurance
05 Pronounced muscle fullness and pumps from increased intracellular water and glycogen
06 Effective oral kickstart while waiting for injectable compounds to saturate
07 One of the fastest-acting anabolic compounds available
VIP
01 Potent vasodilation and blood pressure reduction
02 Strong anti-inflammatory effects
03 Immunomodulation (Th1-Th2 balance)
04 Neuroprotective effects
05 Bronchodilation
06 Cardioprotective (positive inotropic effects)
07 Insulin secretion enhancement (glucose-dependent)
08 Gut barrier and permeability regulation
Dosing Protocols
Dianabol
20-50 mg/day / Split doses throughout the day
VIP
50-100 mcg per dose (up to 200 mcg in research protocols) / 1-2 times daily due to very short 2-minute half-life
General use 50-100 mcg 1-2x daily
Research protocols 100-200 mcg As directed
Side Effects
Dianabol
Significant water retention and bloating (estrogen-mediated)
Elevated blood pressure from fluid retention and increased red blood cell mass
Liver stress with elevated ALT/AST enzymes (dose and duration dependent)
Back pumps (painful lower back cramping during exercise)
Increased appetite
Oily skin and acne
Suppression of endogenous testosterone production (HPTA suppression)
Mild mood changes (increased aggression, irritability, or euphoria)
VIP
Vasodilation (flushing, warmth)
Hypotension
Increased heart rate
Gastrointestinal effects (diarrhea possible)
Headache
Contraindications
Pre-existing liver disease or impaired hepatic function
Active or history of hormone-sensitive cancers (prostate, breast)
Uncontrolled hypertension or significant cardiovascular disease
Elevated hematocrit (above 54%) at baseline
Concurrent use of other hepatotoxic oral steroids (do not stack C17-aa orals)
Pregnancy or potential exposure to pregnant women
Heavy alcohol use (compounded hepatotoxicity risk)
Cholestatic liver conditions or history of drug-induced liver injury
Severe hypotension
VIPoma or related tumors
Pregnancy or breastfeeding
Severe cardiac conditions
Research Evidence
Dianabol VIP
Status Well Studied Extensively Studied
References 5 studies 4 studies
Latest 2017 —
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.